Blindness clinical trials at UCSF

1 research study open to eligible people

Blindness happens when a person loses the ability to see. UCSF is studying Sepofarsen for those with Leber congenital amaurosis, which affects vision. Researchers want to understand if this medication can make a difference.

Showing trials for

  • Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

    open to eligible people ages 6 years and up

    The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A>G (p.Cys998X) mutation in the CEP290.

    San Francisco, California and other locations

Last updated: